
ðºðžCDCçºè¡š: ãæ è¡è ããŒã¹ã®ã²ãã ç£èŠããã°ã©ã ã
以äžã®æç« ã¯ãå人çãªè©Šèš³ã§ãïŒ
ç§å¬ã®åŒåžåšã·ãŒãºã³ã«åããŠãæ è¡è ããŒã¹ã®ã²ãã ç£èŠïŒ Traveler-based Genomic Surveillance )ã¯ãã€ã³ãã«ãšã³ã¶A/BãRSVãSARS-CoV-2ãåã³ãã®ä»ã®åŒåžåšç åäœãæ€æ»ãã錻è ãµã³ããªã³ã°å€ç åäœãã€ãããè©Šéšãéå§ã
BA.2.86ã®ãããªæ°ããéèŠãªSARS-CoV-2äºçš®ã®åºçŸã远跡ããçºã®TGSã®ã²ãã é å決å®ã«é¢ããçŸå Žããã®ã¡ã¢â
ãæ è¡è ããŒã¹ã®ã²ãã ç£èŠããã°ã©ã ãã«ãããSARS-CoV-2ãªãã¯ãã³BA.2.86å€ç°äœã®æ©æçºèŠ ( 2023幎8æ: ãã¬ã¹åœé空枯 )
CDCã®Travelers' Health Branchãäž»å°ãããæ è¡è ããŒã¹ã®ã²ãã ç£èŠããã°ã©ã ïŒTGSïŒãã¯ãå®æ°ããŒãããŒã·ããã«ãããã®ã§ã2ã€ã®äž»èŠç®æšãéããŠç±³åœã®åœå®¶ãã€ãªã»ãã¥ãªãã£ã«éèŠãªåœ¹å²ãæãããŠããã
1) æ°ããSARS-CoV-2äºçš®ããã®ä»ã®ç
åäœã®æ©æçºèŠã
2) äžççãªãã€ãªãµãŒãã€ã©ã³ã¹ã®ã®ã£ãããåããããšã
æŠèŠ
ç±³åœã®ç©ºæž¯ã«ã¯æ¯å¹Ž10å人以äžã®æ
è¡è
ã蚪åã
æ è¡è ã¯ãå ŽæãçŽ æ©ã移åããç åäœãåœå¢ãè¶ããŠæ¡æ£ãããå¯èœæ§ãããçºãæ°åããã³æ°èææçã远跡ããéã«èæ ®ãã¹ãéèŠãªéå£ã§ããã
空枯ã«ãããæŠç¥çãã€ãªãµãŒãã€ã©ã³ã¹ïŒç£èŠïŒã¯ãSARS-CoV-2äºçš®ãå ¬è¡è¡çäžéèŠãªãã®ä»ã®ç åäœãã¿ã€ã ãªãŒã«æ€åºããããšãå¯èœã«ããã
ããã°ã©ã ã®åœ±é¿
1)
æ°èææçã®è
åšãã»ãŒãªã¢ã«ã¿ã€ã ã§æ€ç¥ããæ©æèŠæã·ã¹ãã ãæäŸã
TGSã¯ãäžççã«å ±åãããæ倧6é±éåã«ã以äžã®ãããªæ°å€ãã®ãªãã¯ãã³ã®äºçš®ãæ€åºã
ba.2ãba.3ãbq.1ãbq1.1ãxbbãch.1.1ãxbc.1.6ãbq.1.2.2
2)
å
¬è¡è¡çåœå±ãžã®è¿
éãªæ
å ±æäŸãåã³ç±³åœé£éŠç 究æãžã®ãµã³ãã«æäŸã«ãããçŸç
çºçãåºç¯å²ã«åœ±é¿ãåãŒãåã«å¶å§ããäºãæ¯æŽã
TGSã¯ãSARS-CoV-2ã²ãã é åã®å šç±³ç¬¬2äœã®æäŸè ã§ããã
3)
æ€æ»ãã·ãŒã¯ãšã³ã·ã³ã°ã»ããŒã¿ãå
¥æäžå¯ã®å Žåãäžççãªç£èŠïŒãµãŒãã€ã©ã³ã¹ïŒã®ã®ã£ãããåããã
TGSã¯ãäžçä¿å¥æ©é¢ïŒWHOïŒã®å šå°åãã135ã«åœä»¥äžã幎éçŽ30äžäººã®æ è¡è ãç»é²ããŠããã
4)
äŒæç
ã®è延é²æ¢ãåœå¢ä»å
¥ãæ
è¡ã»è²¿æã®äžæã®å¿
èŠæ§ãåé¿ããã®ã«åœ¹ç«ã€ã
2022幎12æã«äžåœã§çºçããCOVID-19ã®æ¥å¢ã®éãTGSã¯è¿œå ã®ç©ºæž¯ã«è¿ éã«æ¡å€§ãäžåœããã®250䟿以äžãšãåšèŸºã®äº€éãããã«ããŒããããšã§ããµã³ãã«ãè¿ éåéããäžåœã§åŸªç°ããŠããå€ç°äœã«é¢ããæ å ±ãæäŸããããšãåºæ¥ãã
ä»çµã¿
æ
è¡è
ãµã³ããªã³ã°ã»ããã°ã©ã
åå æ
è¡è
ããæ¡åãããåã
ã®ãµã³ãã«ã¯ãSARS-CoV-2äºçš®ããã®ä»ã®ç
åäœãæ€åºããçºã®æã詳现ã§ä¿¡é Œæ§ã®é«ãããŒã¿ãšãªãã
ãµã³ãã«ã¯å
šãŠä»»æãå人ç¹å®ããªãã
åå è
ã¯ç°¡åãªã¢ã³ã±ãŒãã«çããããšã§ããããã®ãµã³ãã«ã«ä»éããè±å¯ãªã¡ã¿ããŒã¿ãæäŸãå
¬è¡è¡çã®ææ決å®ã«æ
å ±ãæäŸããã
錻è ãµã³ãã«ã¯CDCã®ç 究æã«è»¢éãããæŽãªãæ€æ»ãåããããšãåºæ¥ãã
2021幎9æã«æŠå¿µå®èšŒãããžã§ã¯ããæåããåŸããã®ããã°ã©ã ã¯æ¡å€§ãçŸåšç±³åœã®äž»èŠåœé空枯6ã«æã§å®æœãããŠããã
1)
åå 空枯ã«å°çããå€åœäººæ
è¡è
ã¯ã錻è
ã¬ãã液ã®èªå·±æ¡åãå¿é¡ããã
2)
ãµã³ãã«ã¯ãSARS-CoV-2é転åé
µçŽ ããªã¡ã©ãŒãŒé£éåå¿ïŒRT-PCRïŒæ€æ»ã®çºã«æ€æ»æœèšãããã¯ãŒã¯ã«éãããã
3)
éœæ§ãµã³ãã«ã¯å
šã²ãã é
å決å®ãåããå€ç°åã決å®ãããã
4)
éžæãããTGSãµã³ãã«ã¯ãCDCã®ç 究宀ãšå
±æãæ°ããå€ç°åã®æææ§ãç
åæ§ãçŸåšã®æ²»çæ³ãã¯ã¯ãã³ã«å¯Ÿããåå¿æ§ã«é¢ããæ
å ±ãæäŸãããŠã€ã«ã¹ç¹æ§è§£æãè¡ãããã
å®æœç©ºæž¯â
ã錻è
ã¬ãã液ã®èªå·±æ¡åãã®ã¿
ãã¹ã»ã¢ã³ãžã§ã«ã¹ / ãã¥ãŒã¢ãŒã¯ ãã·ã¢ãã«ãã¯ã·ã³ãã³DC (IAD)
ç²ç æ©ã®ã¿
ãã¹ãã³
ã錻è
ã¬ãã液ã®èªå·±æ¡åãïŒãç²ç æ©ã
ãµã³ãã©ã³ã·ã¹ã³
ã錻è
ã¬ãã液ã®èªå·±æ¡åã+ãèªç©ºæ©ææ°Žã
ãã¥ãŒãšãŒã¯ ( JFK )

é£è¡æ©ã®ææ°Žãµã³ããªã³ã°ã»ããã°ã©ã
å»æ°Žæ€æ»ã¯ãã¢ãŠããã¬ã€ã¯ããã³ãããã¯ã®æ€åºã«åœ¹ç«ã¡ãæ¥éã«å°é ãã€ã€ããç§åŠã§ããã
å°åã¬ãã«ã®å»æ°Žããã°ã©ã ã¯ãSARS-CoV-2ããã®ä»ã®ç
åäœã®æ€åºã«æåã
èªç©ºæ©ã«ããå»æ°Žç£èŠã¯ãäžççã«æµè¡ããŠããç åäœãç£èŠããããããå°å瀟äŒã«åºããåã«æ©æã«çºèŠããçºã®å¹æçã»äœã³ã¹ãã®ããŒã«ã
å»æ°Žã®ç£èŠã«ã¯ããµã³ãã«ãæ¡åããçºã«æ è¡è ãçŽæ¥é¢äžïŒåå ããå¿ èŠãç¡ããšããå©ç¹ãããã
ææ°Žãµã³ããªã³ã°ã®åãåºãäœæ¥â

2022幎8æ以æ¥ãCDCã¯èªç©ºæ©ã®ææ°Žãµã³ããªã³ã°ãè¡ã£ãŠããã
ãã®èªç©ºæ©å»æ°Žããã°ã©ã ã¯çŸåšãè©Šéšæ®µéããããåºç¯ãªå®æœãžãšæ¡å€§ã
å»æ°Žã¯ãç¹æ³šã®åéè£
眮ãçšããŠåéãããã
ææ°Žãµã³ãã«ã¯ãRT-PCRæ€æ»ã®çºã«ç 究宀ã«éãããã
éœæ§ãµã³ãã«ã¯ãå
šã²ãã é
å決å®ãåããŠãå€ç°äœã決å®ããã
空枯ããªãã¥ã¬ãŒã¿ãŒïŒç²ç æ©ïŒææ°Žãµã³ããªã³ã°ã»ããã°ã©ã
2023幎4æ以éããµã³ãã©ã³ã·ã¹ã³ã§ã¯ç©ºæž¯ããªãã¥ã¬ãŒã¿ãŒã®èªåãµã³ãã©ãŒè£
眮ã䜿çšããŠå»æ°Žãµã³ãã«ãæ¡åããŠããã
ç²ç æ©ã¯ãè€æ°ã®ãã©ã€ãããææ°Žãµã³ãã«ãæ¡åããéçŽå°ç¹ã§ããã空枯ã¿ãŒããã«ã®å»æ£ç©ã¯å«ãŸããªãã
çŸç
ç£èŠã®æªæ¥ããªãŒããã
æž¡èªè
ããŒã¹ã®ã²ãã ç£èŠã¯ãSARS-CoV-2以å€ã«ãå€ãã®ç
åäœã®æ©æèŠæã·ã¹ãã ãšããŠäœ¿çšã§ããç
åäœæ€åºã®ã¢ãã«ã
ä»åŸã®èª²é¡â
1)
æž¡èªè
ããã°ã©ã ãšææ°Žããã°ã©ã ã®äž¡æ¹ã§ãè€æ°ã®ç
åäœã®æ€æ»ãæ¡å€§ã
2)
èªç©ºæ©ã«ããå»æ°Žç£èŠã®äžççãããã¯ãŒã¯æ§ç¯ã®çºã®ããŒãããŒã·ããæ§ç¯ã
3)
äžççãªå€§èŠæš¡éäŒïŒç§»äœã€ãã³ãã«å¯Ÿããç£èŠèœå匷åã
- INFO SOURCE -
CDC homepage ( 27th October 2023 )
https://wwwnc.cdc.gov/travel/page/travel-genomic-surveillance#howitworks